Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a big gap between 2.25 and 10. Heck there is a big gap between 2.25 and 2.50 and on millions of shares, yes significant selling would commence and opportunities sometimes only last a matter minutes. The lenders know when patents are lapsing and what that means. They know what the track record is for sales. They know not to be greedy.
Amen, these tools have zero influence on any stock.
Good luck with that
Nothing posted here makes a difference lol
No one follow IHUB anymore
All the action in on other more modern social media platforms
The hype should well outweigh any slow conversion
I am in it for a swing, not married to it
I think $5+ is possible and higher if it squeezes
Dude either buy the stock or not, stop with the ihub basher bullshit. You cockroaches really need to get a life, grow up!! Gfo
There is no advantage to buy warrants at the warrant price
The price needs to be much higher for that option to be attractive
Glad to see you're getting my point. I was using approx 1 million shares per month as share price has been lower than current price. Could be 800k. Could be less but its a formula. Company needs the volume to sell the shares. I'm not judging whether there is enough volume or not, or what might happen when the warrant shares start hitting the market if the price gets above 2.25. It's a lot of shares and will be like that all year it looks like. I'm not predicting share price here but simply put, folks should know what they own and what could influence the price. No one has any clue if AI will help sales significantly or not. If it does, another company's generic could potentially be on the market later next year. A lot is up in the air. Competition for OTC has heated up as well. In other words trying to keep it real. Not trying to short. Not hoping anyone loses money. Just hoping no one becomes a bag holder. It's happened several times here. I follow because I owned a company that was part of the original reverse merger and spinoff that allowed Petros to get the Nasdaq listing. I sold my free shares from the spinoff well before the the last reverse split at above 5 bucks, equivalent to many, many, many times the current share price. Maybe that answers more questions. JMHO
$PTPI 👀
$PTPI pic.twitter.com/7fcUCmNpXO
— Keith Rah (@keith_rah) February 27, 2024
So to be fair I did some serious calculations on the 13 installments
This month the instalment added around 800k shares to the float
That’s only 40k shares per day to absorb
That’s like 5% of our volume today
Bottom line, there is plenty of daily volume to absorb the instalment conversions during March and run it and the higher the pps the less number of shares needed for the instalment
You worry too much lol
PS: assuming the company did not opt to pay the instalment in cash at 107% …
Understood. I don't believe there is any significant FDA news in March but you're correct there
could be a lot of hype that could lead into some warrants being cashed in.
I expect hype into the FDA meetings and associated pps going much higher
So you expect Fda results in "march" or do you expect meetings where at a later date the public will be made aware of any discussions. My understanding is the 1st meeting will be "listen only" and a second type C meeting is scheduled for March 26. When do you predict we hear from that? Will it be in March?
There will be no FDA results in March. It's just meetings. if it's $10 then 7 million warrants would have been cashed in FYI. I figured no response as to how the installments were to be made. Free money out in cyberspace I guess
You focus on instalments lol
I will focus on FDA results in March and $10+
EOW includes the March 1st installment payment. So that's 5 months of installments that have to be accounted of which you account for NONE, although they are specifically and legally mentioned in the most recent quarterly. My earlier posts gave the calculations for dilution to pay back directly from the 10Q. What do you think that the O/S number will be after this week and based on what calculations? My guess is you won't answer. I'll say again it seems also suspect to be focused on the least meaningful aspect of this story (dilution) instead of a lapsing patent, poor sales, financial losses, or a recently launched OTC ED product .
Bro you said 8m OS by EOW
Your credibility is zero
They didn't have to start making the installments until November. Convertible Notes don't dilute until the payments have to be made. Dilution has to come. How else do they pay the notes back? I'm just reading from the filings. The company bleeds cash. They have to pay in stock. It has to show up at some point right? I don't care if the O/S is 3 million or 15 million. They just had to reverse split to get the number so low. Any idea what the O/S were before that? It's convertible 101. I would be more concerned about the patent and 25+ million in Notes debt than what the heck the share count is. Someone asked. I gave my opinion. Dilution is coming at some point. If you don't think that, then you're the one with no credibility. It doesn't matter what the share count is today IMO
Speaking of filings …
Look at all that dilution from May to Nov 2023
Thats 6 months worth fyi
As of May 15, 2023, there were 2,113,570 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.
As of November 14, 2023, there were 2,201,069 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.
Post 435 and I even bolded parts for folks that don't understand or like to read filings. What about filings scares folks so bad?
What's interesting is not a single person has suggested how these 13 installment payments are being taken care of. Money ain't free. Maybe there is a Nasdaq rule that won't allow for this massive dilution all at once. I don't know. That wouldn't be good. What I do think is money ain't free and drugs 12 years into a a patent cycle don't become blockbuster due to some AI. There actually is an OTC product for ED that was approved last fall but all this great twitter DD isn't mentioning that.
What I don't understand is what the fascination is of the exact number of shares and why someone would stick to a more than 3 month old number when the filings are repeatedly shown regarding payment of the notes. If its 3 million or 8 doesn't matter if you can't pay your bills in cash or have to pay in stock. Sales are poor, patent expires in little over a year, and multiple Notes are due monthly and even yearly. I'm just pointing out the filings. If the company can't sell enough stock, that wouldn't really be a good thing would it?
Oh your 8m already down to 3m
Oops caught in a lie
Yawn…
Still waiting for your justification of your 8m OS claim by EOW lmfao
Ooops BS caught
Interesting that you can read tweets and not understand that the drug has been a dud for over a decade, yet can't understand that the company owes over 25 million in notes with no idea how its being paid back other than how its explained in the filings. Apparently loans are free money out in social media land. Good grief. If the share count isn't significantly higher than 3 million now, it will be at some point this year. The filing says 13 monthly installments starting last November. Simply tell me how you think that it has been paid back in November, December, January, and February. Folks can bury their head and not read the filings but that typically leads to bagholders at some point, whenever that might be. Using cash balances from last summer and share counts from November and then pretend anyone who says otherwise is short, might not be the best way to invest. Some have have claimed trading at 1/5 cash value when they don't know the cash balance or the share balance or understand 25+ million is owed.
$PTPI understanding the OTC process
Two tweets explaining it
1/2
$PTPI - (1/2) 🧵What is the new FDA ACNU rule and how does it relate to $PTPI? - This innovative rule was proposed in July 2022 and the purpose was to streamline the approval process for the RX-to-OTC switch and empower patients to actively participate in their self-care. An… pic.twitter.com/3nL0twnCKX
— Calvin (@Calvin65883332) February 27, 2024
(2/2) 🧵 To speed up the time to commercialization $PTPI has decided to build their own ML/AI platform to accelerate the RX-to-OTC approval process including the final patient self-selection process. This speeds up GTM time drastically.
— Calvin (@Calvin65883332) February 27, 2024
Remember: This platform could be used for… pic.twitter.com/e6fXawihBl
$PTPI public starting to notice
Petros Pharma Introduces AI as ACNU Option - First to Introduce OTC Switch Labeling Tool #PTPI pic.twitter.com/XudEuoJClP
— Calvin (@Calvin65883332) February 27, 2024
Nope
Nice try
You have not shown how the OS is at 8m by eow
Total BS
It's in my posts. Apparently you didn't read my quotes from the 10Q. Not surprising. How do you think the monthly installments have been paid these last few months? I've already explained where my numbers come from. You won't read my posts or the filings apparently. They've either been paying in shares, cash, or they still owe over 25 million in notes it looks like to me
Still avoiding my simple question
You full of $hit
How is a November 14 share count proving anyone lying?
How much to they owe each month? I showed you how they figured the payment. Do the math. They are either paying it or they owe it. It's pretty simple. When you have 25 million owed in notes you have to pay some how. You don't bury your head in the sand
Show me how you came to 8m
Stop avoiding the question
My facts proved you were lying
Typical response with no backing
Your true colors exposed
Clearly u did not watch the interview
Read the last 10q. How are they paying the monthly installments on the 15 million dollar note? They either owe the money or are paying in shares. How many times do I have to use the company's own language from the 10Q. Loans aren't free
Now that is funny.
So why don’t you explain how you came to 8m which is an outright lie
You’re credibility is zero
All explained in interview
AI is the last piece to the solution
By end of March this will see $10+ in my opinion
Yawn …
Cover your short lol
Current OS and float are small at $1.60
That’s all traders care about.
As long as folks understand that the CEO was marketing this drugs for years, even before he was CEO here. He's had a long time to increase sales. It hasn't happened. This month's type C FDA meeting on the 26th will take some time to even hear back. That means less than a year left on the patent if the company's own filings are correct. I'm just projecting o/s based on the company paying their 13 monthly installments with shares as the 10k says is required. They have to pay with either shares or cash. They don't want to spend the cash they have I would imagine. If they have delayed the payments then its just a matter of time before the dilution occurs. Can someone tell me how they pay back the 15 million convertible note and the other 10.2 million note that is due in yearly installments without burning cash or significant dilution? I mean CEO videos are great but this isn't a start up situation. The drug was approved in 2012. That's why the patent runs out next year.
Only in the message board world when a poster states they could see the price move from current to over 2.25 would they be considered a short. Don't be the last man standing is my opinion.
How are they paying the monthly installments from last summer's note then? This is from the last quarterly filed page 23. If I'm wrong show me where. I'll admit it.
We are required to redeem the Series A Preferred Shares in 13 equal monthly installments, commencing on November 1, 2023. The amortization payments due upon such redemptions are payable, at our election, in cash at 107% of the Installment Redemption Amount (as defined in the Certificate of Designations), or subject to certain limitations, in shares of common stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the three lowest closing prices of the common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $0.396, which is 20% of the “Minimum Price” (as defined in Nasdaq Stock Market Rule 5635) on the date of the Nasdaq Stockholder Approval (as defined below) or such lower amount as permitted, from time to time, by the Nasdaq Stock Market, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events.
Correct
That CEO interview answered all my questions and now I am more confident than ever
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
549
|
Created
|
12/04/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |